Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 1,341–1,360 of 17,937 drug recalls

Drug Recall Terminated Historical recordClass II

Burkhart, Topical Anesthetic Gel, Benzocaine 20%, Gluten Free, 1 FL. OZ (30 ml), Manufactured for Burkhart Dental Supply, Tacoma, Washington 98409.

by Keystone Industries

Reason
CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.
Recall initiated
November 14, 2024
Reported by FDA
December 25, 2024
Distribution
Nationwide in the USA and Canada, Dominican Republic, El Salvador, Honduras, and Qatar.

View recall →

Drug Recall Terminated Historical recordClass II

Health-Tec, Topical Anesthetic Gel, Benzocaine 20%, Made in USA, 1 FL. OZ (29.6 ml), NDC 69634-021-30.

by Keystone Industries

Reason
CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.
Recall initiated
November 14, 2024
Reported by FDA
December 25, 2024
Distribution
Nationwide in the USA and Canada, Dominican Republic, El Salvador, Honduras, and Qatar.

View recall →

Drug Recall Terminated Historical recordClass II

Patterson Dental, Patterson Topical Anesthetic Gel, Benzocaiine, 1 oz. (30 ml), Manufactured for (Fabrique pour): Patterson Dental Supply, Inc. 1031 Mendota Heights Road, Saint Paul, MN 55120, NDC 50227-1002-3.

by Keystone Industries

Reason
CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.
Recall initiated
November 14, 2024
Reported by FDA
December 25, 2024
Distribution
Nationwide in the USA and Canada, Dominican Republic, El Salvador, Honduras, and Qatar.

View recall →

Drug Recall Terminated Historical recordClass II

Dental City, Topical Anesthetic Gel, Benzocaine 20%, Net Content: 1 oz. (30 ml), Gluten Free, Manufactured for: Dental City, Green Bay, WI 54311, dentalcity.com.

by Keystone Industries

Reason
CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.
Recall initiated
November 14, 2024
Reported by FDA
December 25, 2024
Distribution
Nationwide in the USA and Canada, Dominican Republic, El Salvador, Honduras, and Qatar.

View recall →

Drug Recall Terminated Historical recordClass II

Primo, Topical Anesthetic gel, Benzocaine 20%, Net Content: 1 oz. (30g), Gluten Free, Manufactured for: Primo Dental Products, 845 Third Avenue, 6th Floor, New York, NY 10022.

by Keystone Industries

Reason
CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.
Recall initiated
November 14, 2024
Reported by FDA
December 25, 2024
Distribution
Nationwide in the USA and Canada, Dominican Republic, El Salvador, Honduras, and Qatar.

View recall →

Drug Recall Terminated Historical recordClass II

M&S Dental Supply Co LLC., Topical Anesthetic Gel, Benzocaine 20%, Net Wt. 1 oz. (30ml), Manufactured for: M&S Dental Supply Co LL, 105-30 101 Avenue, Ozone Park, NY 11416.

by Keystone Industries

Reason
CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.
Recall initiated
November 14, 2024
Reported by FDA
December 25, 2024
Distribution
Nationwide in the USA and Canada, Dominican Republic, El Salvador, Honduras, and Qatar.

View recall →

Drug Recall Terminated Historical recordClass II

Gelato, Benzocaine 20% Topical Gel Anesthetic Gel, Net Wt. 1 oz. (30ml), Manufactured by Keystone Industries 480 S. Democrat Rd., Gibbstown, NJ 08027, NDC# 68400-352-30.

by Keystone Industries

Reason
CGMP deviations: the bulk product was rejected by the Quality Unit after routine inspection of the mixing vessel showed scratches on the sides and bottom of the mixing vessel. Product was to be rejected but was inadvertently released and shipped to customers.
Recall initiated
November 14, 2024
Reported by FDA
December 25, 2024
Distribution
Nationwide in the USA and Canada, Dominican Republic, El Salvador, Honduras, and Qatar.

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 175 mcg (0.175 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-040-20

by Mylan Institutional, Inc.

Reason
Subpotent and Superpotent Drug
Recall initiated
November 19, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide in the USA.

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 150 mcg (0.150 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-445-20

by Mylan Institutional, Inc.

Reason
Subpotent and Superpotent Drug
Recall initiated
November 19, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide in the USA.

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 137 mcg (0.137 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-041-20

by Mylan Institutional, Inc.

Reason
Subpotent and Superpotent Drug
Recall initiated
November 19, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide in the USA.

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 125 mcg (0.125 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-443-20

by Mylan Institutional, Inc.

Reason
Subpotent and Superpotent Drug
Recall initiated
November 19, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide in the USA.

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 112 mcg (0.112 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 42292-039-20

by Mylan Institutional, Inc.

Reason
Subpotent and Superpotent Drug
Recall initiated
November 19, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide in the USA.

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets, USP, 100 mcg (0.1 mg), 100 Tablets per carton (10 unit dose blister cards of 10 tablets each), Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-442-20

by Mylan Institutional, Inc.

Reason
Subpotent and Superpotent Drug
Recall initiated
November 19, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide in the USA.

View recall →

Drug Recall Ongoing Historical recordClass II

Dabigatran Etexilate, 150mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-475-60

by Ascend Laboratories, LLC

Reason
CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
Recall initiated
December 12, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide within the United States

View recall →

Drug Recall Ongoing Historical recordClass II

Dabigatran Etexilate, 75 mg capsules, 60-count bottles, Rx Only, Manufactured by: Alkem Laboratories Ltd., INDIA, Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054 NDC 67877-474-60

by Ascend Laboratories, LLC

Reason
CGMP Deviations: Presence of N-nitroso-Dabigatran impurity above recommended interim limit
Recall initiated
December 12, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide within the United States

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 112 mcg, packaged in a) 90-count bottles (NDC 0378-1811-77) and b) 1000-count bottles (NDC 0378-1811-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason
Superpotent Drug and Subpotent Drug: potency failures obtained
Recall initiated
November 18, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide within the United States and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 100 mcg, packaged in a) 90-count bottles (NDC 0378-1809-77) and b) 1000-count bottles (NDC 0378-1809-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason
Superpotent Drug and Subpotent Drug: potency failures obtained
Recall initiated
November 18, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide within the United States and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 88 mcg, packaged in a) 90-count bottles (NDC 0378-1807-77) and b) 1000-count bottles (NDC 0378-1807-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason
Superpotent Drug and Subpotent Drug: potency failures obtained
Recall initiated
November 18, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide within the United States and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 75 mcg, packaged in a) 90-count bottles (NDC 0378-1805-77) and b) 1000-count bottles (NDC 0378-1805-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason
Superpotent Drug and Subpotent Drug: potency failures obtained
Recall initiated
November 18, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide within the United States and Puerto Rico

View recall →

Drug Recall Ongoing Historical recordClass II

Levothyroxine Sodium Tablets USP, 50 mcg, packaged in a) 90-count bottles (NDC 0378-1803-77) and b) 1000-count bottles (NDC 0378-1803-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.

by Viatris Inc

Reason
Superpotent Drug and Subpotent Drug: potency failures obtained
Recall initiated
November 18, 2024
Reported by FDA
December 18, 2024
Distribution
Nationwide within the United States and Puerto Rico

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.